摘要
背景慢性呼吸困难会带来毁灭性的后果。最小临床重要差异(MCID)电流强度在100毫米视觉模拟量表(VAS)上估计为9毫米。我们的目标是确定常用维度和回忆周期的mcid:目前的不愉快和当前,平均,最好的和最差强度of the last 24 h for chronic breathlessness.
方法这是吗啡的随机对照试验的二次分析与期间,人们从严重的疾病慢性呼吸困难7天安慰剂。The breathlessness scores were self-reported using a diary each evening on 100 mm VAS. The MCID for improvement in each score was estimated using anchor based and distribution based methods.
结果283 participants (mean age 74.2 years; 63% males; 58% COPD; 87.0% mMRC 3–4) were included. Anchor-based MCIDs for breathlessness scores ranged from −13.9 mm to −9.5 mm. The MCIDs were similar when using different anchors and across all participants, and participants with more severe BREATHLESSNESS (mMRC 3–4), respectively. Distribution based effect sizes were: small (−4.7 to −6.3 mm), moderate (−9.4 to −12.5 mm) and large effect (−15.0 to −20.0 mm). Sample sizes for trials using the different scores were proposed. MCIDs of absolute change were more stable than using relative change from baseline.
结论An improvement of about 10 mm on a 100 mm VAS is likely to be clinically meaningful across commonly used measures of chronic breathlessness (电流强度,不愉快,和平均,最好的和最差过去24小时内的强度-评估治疗试验中的临床效益和效果。
脚注
这篇手稿最近被接受在欧洲呼吸杂志。据审稿,并通过我们的制作团队排版之前在这里其已接受的形式出版。经过这些生产工艺齐全,作者已经批准了造成证据,文章将移动到的最新一期厄尔吉在线。请打开或下载PDF以查看本文。
利益冲突:埃克斯特伦博士没有什么要透露的。
利益冲突:约翰逊博士没有什么要透露的。
利益冲突:黄博士没有什么可以透露的。
利益冲突:Currow博士是Helsinn Pharmaceuticals咨询委员会的无薪成员,是专业治疗学和梅恩制药公司的顾问,并从梅恩制药公司获得知识产权付款。
- 收到2019年11月14日。
- 公认2020年4月14日。
- 版权所有©ERS 2020